Advertisement
Skip to Content

Opthea Ltd CKDXF Stock Quote

| Rating as of

PINX: CKDXF

Last close prices updated as of Jun 01, 2023, 1:53 PM EST | USD
  • Last Close 0.42
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Blend
  • Day Range 0.41  –  0.42
  • Year Range 0.41  –  0.82
  • Market Cap 196.1058 Mil
  • Volume / Avg 30,000.0 /  17,503.0
  • Price / Sales 1,759.55
  • Price / Book 3.47
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis CKDXF

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics CKDXF

Company Profile CKDXF

Business Description

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

Contact
650 Chapel Street, Level 4, Suite 0403
South Yarra, VIC, 3141, AUS
Industry Biotechnology
Employees 18

Competitors & Peers CKDXF

Morningstar does not cover competitors or peers for this firm.

FAQs for Opthea Ltd Stock

No. CKDXF does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

CKDXF’s market cap is 196.11 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

CKDXF’s stock style is Small Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

CKDXF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare CKDXF’s historical performance against its industry peers and the overall market.